Metabolic Management
|
November 15, 2024

Patients Over 40 With Elevated Cholesterol Should Consider These 5 Lab Tests Yearly

Medically Reviewed by
Updated On
November 20, 2024

Elevated cholesterol is a common health concern, affecting 73.5 million American adults. As cholesterol levels rise, so does cardiovascular disease (CVD) risk. For example, people with high cholesterol have twice the risk for heart disease compared to people with normal levels. 

However, as our understanding of CVD expands, we recognize that cholesterol is just one factor among many that determines cardiovascular risk. Genetic predisposition, lifestyle factors, inflammation, thyroid function, glucose metabolism, and liver health all contribute to an individual's overall heart health. 

Relying solely on traditional lipid panels may not accurately represent cardiovascular risk, especially for patients over 40 with overlapping risk factors. To thoroughly evaluate and effectively manage cardiovascular risk, consider incorporating these five lab tests into routine check-ups for patients over 40 with high cholesterol. 

[signup]

Understanding Cholesterol

Cholesterol is a waxy, fat-like substance found in the blood and in every cell of the body. It maintains the integrity and fluidity of cell membranes and serves as a precursor for steroid hormones, bile acids, and vitamin D. The liver produces all the cholesterol the body needs, but it can also be obtained from animal-derived dietary sources.

There are two main types of cholesterol: 

  • Low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol
  • High-density lipoprotein cholesterol (HDL-C), known as "good" cholesterol 

Elevated levels of LDL-C can lead to the buildup of plaque in the arteries, increasing the risk of coronary artery disease, heart attack, and stroke. Conversely, HDL-C helps remove cholesterol from the bloodstream, conferring protection against CVD. (36) 

The American College of Cardiology and the American Heart Association (ACC/AHA) emphasize managing blood cholesterol levels to prevent atherosclerotic cardiovascular disease (ASCVD). They recommend regular monitoring and lifestyle modifications, including diet and exercise, to maintain healthy cholesterol levels.

Why Monitor Cholesterol in Patients Over 40?

Elevated LDL-C is a well-established risk factor for ASCVD. Studies consistently show that higher LDL-C levels correlate with increased rates of ASCVD events and cardiovascular mortality:

  • A meta-analysis involving over 1.2 million participants demonstrated that LDL-C levels ≥ 130 mg/dL were associated with a higher risk of all-cause mortality and CVD events compared to LDL-C levels of 70-129 mg/dL.
  • A study with a median follow-up of 26.8 years found that LDL-C levels ≥ 160 mg/dL were independently associated with a 50-80% increased relative risk of cardiovascular mortality.

The risk of high cholesterol increases with age. Physiological changes, such as changes in cholesterol synthesis, lipid metabolism, and hormonal shifts, contribute to higher cholesterol levels as an individual ages. This is why the 2018 AHA/ACC guidelines emphasize ASCVD risk assessment and management in adults aged 40 to 75. 

Top 5 Annual Lab Tests for Patients Over 40 with Elevated Cholesterol

These five lab tests should be ordered at least once a year for patients over 40 with high cholesterol.

Lipid Panel

A lipid panel is a routine blood test that measures the amount of lipids in the blood. A basic lipid panel will include: 

  • Total cholesterol (TC)
  • LDL-C
  • Very-low-density lipoprotein cholesterol (VLDL-C)
  • HDL-C
  • Triglycerides (TG)

Why It's Important

  • Risk Assessment: It helps identify individuals at high risk for atherosclerotic ASCVD and guides the initiation of preventive measures, such as lifestyle modifications and statin therapy. (15, 51) 
  • Monitoring Therapy: It is used to monitor the effectiveness of lipid-lowering therapies and make necessary treatment adjustments. (5, 51) 

Frequency of Ordering a Lipid Panel

  • The ACC and AHA recommend that adults aged 40 to 75 undergo a lipid panel every 4 to 6 years if they are not on lipid-lowering therapy (10). 
  • For patients on statin therapy, a lipid panel should be obtained at baseline, 4-12 weeks after initiation or dose adjustment, and then every 3-12 months as needed to monitor response and adherence (51). 

Examples of Lipid Panels

High-sensitivity C-reactive Protein (hs-CRP)

hs-CRP is an inflammatory biomarker that measures low levels of C-reactive protein in the blood, which is produced by the liver in response to inflammation. It is a more sensitive measure than standard CRP tests and can detect lower levels of inflammation.

Why It's Important

hs-CRP is a strong independent predictor of future cardiovascular events, including myocardial infarction (heart attack) and stroke, even in individuals without overt hyperlipidemia. Elevated hs-CRP levels indicate a higher risk of ASCVD due to underlying inflammation. (69, 70) 

The JUPITER trial demonstrated that statin therapy significantly reduces cardiovascular events in patients with elevated hs-CRP (>2 mg/L) but normal LDL-C levels (<130 mg/dL). This suggests that hs-CRP can help identify patients who may benefit from statin therapy despite not meeting traditional cholesterol criteria. (48) 

Examples of hs-CRP Tests

Thyroid Function Tests 

Thyroid function tests are a series of blood tests used to evaluate the function of the thyroid gland. These tests typically include measurements of:

  • Thyroid-stimulating hormone (TSH)
  • Free thyroxine (fT4)
  • Free triiodothyronine (fT3)

Why It's Important

Thyroid hormones heavily influence lipid metabolism. Hypothyroidism, characterized by elevated TSH and low fT4/fT3, is associated with increased levels of TC, LDL-C, and TG and decreased levels of HDL-C. This relationship is well-documented in the literature, including studies showing that even within the euthyroid range, variations in thyroid hormone levels can influence lipid profiles. (52, 55, 84, 85) 

Thyroid dysfunction should be ruled out as a contributing factor in patients with high cholesterol. Even subclinical hypothyroidism, where TSH is elevated, but fT4 and fT3 are within normal ranges, can also lead to dyslipidemia and increased cardiovascular risk (44). Identifying and treating thyroid dysfunction can help normalize lipid levels and reduce cardiovascular risk.

Frequency of Thyroid Function Testing

Order thyroid function tests at baseline in patients with high cholesterol to identify any underlying thyroid dysfunction. 

The American Thyroid Association recommends screening for thyroid dysfunction every five years in adults, beginning at 35 years. Individuals at high risk for thyroid disorders should be screened more frequently.

If thyroid dysfunction is detected and treated, thyroid hormone levels should be rechecked 6-10 weeks after initiating or modifying treatment, and subsequently every 6-12 months as long as the patient remains stable.

Examples of Thyroid Function Tests

Liver Function Tests 

Liver function tests (LFTs) are blood tests that measure various enzymes produced by the liver. These tests typically include: 

  • Alanine transaminase (ALT)
  • Aspartate transaminase (AST)
  • Alkaline phosphatase (ALP)
  • Gamma-glutamyl transferase (GGT)

Why It's Important

The liver plays a central role in cholesterol synthesis and metabolism. Elevated LFTs can indicate liver dysfunction, such as metabolic-associated fatty liver disease (previously termed non-alcoholic fatty liver disease), which can adversely affect lipid profiles and the body's ability to manage cholesterol.

Assessing and monitoring liver function is also important for patients who require statin therapy. Statins can cause mild elevations in liver enzymes, and monitoring helps ensure that these elevations do not progress to significant liver injury.

Examples of Liver Function Tests

Blood Glucose and Hemoglobin A1c

Blood glucose tests measure the concentration of sugar in the blood at a specific point in time. Tests can either be fasting or random (non-fasting). Elevated blood glucose levels can indicate impaired glucose metabolism, which often coexists with dyslipidemia and increases cardiovascular risk. (12) 

Hemoglobin A1c (HbA1c) measures the percentage of glycated hemoglobin to reflect the average blood glucose levels over the past 2-3 months. It is a reliable marker for chronic hyperglycemia and is used to diagnose diabetes (≥6.5%) and prediabetes (5.7%- 6.4%).

Why It's Important

Hyperglycemia is another major risk factor for CVD. Elevated HbA1c levels are associated with atherogenic dyslipidemia – patients with elevated HbA1c tend to also have higher TC, LDL-C, and TG. 

Effective management of both dyslipidemia and hyperglycemia can significantly reduce the risk of cardiovascular events. Studies demonstrate that improved glycemic control can lead to atheroprotective changes in lipid profiles.

Frequency of Measuring Blood Sugar

According to the American Diabetes Association (ADA), screening for diabetes should begin at age 35 for all adults. If results are normal, testing should be repeated at a minimum of three-year intervals. More frequent testing may be considered based on initial results and risk status. 

Those with prediabetes should be tested annually to monitor blood sugar control and prevent progression to diabetes (68).

HbA1c should be measured in patients who have been diagnosed with diabetes at least twice a year if they are stable and meeting treatment goals and quarterly (every three months) if therapy changes or goals are not being met (4). 

Examples of Blood Glucose and HbA1c Tests

Additional Lab Tests to Consider

Innovations in lipid profiling provide a more nuanced understanding of cardiovascular risk compared to traditional lipid panels. Novel biomarkers offer deeper insights into cardiovascular risk.

Lipoprotein(a)

Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein associated with increased ASCVD risk. Elevated Lp(a) levels (>50 mg/dL or >125 nmol/L) are considered a risk-enhancing factor, particularly in individuals with a family history of premature ASCVD or unexplained personal history of ASCVD. Measuring Lp(a) can help stratify cardiovascular risk and guide more aggressive lipid-lowering therapy. (50, 64) 

Examples of Lp(a) Tests

Apolipoprotein B

Apolipoprotein B [ApoB] represents the total number of atherogenic lipoprotein particles, including LDL, VLDL, and intermediate-density lipoprotein (IDL). ApoB is a better predictor of ASCVD risk than LDL-C, especially in patients with hypertriglyceridemia or metabolic syndrome. An ApoB level >130 mg/dL is considered a risk-enhancing factor and can guide the intensification of lipid-lowering therapy. (42, 77) 

Examples of ApoB Tests

Homocysteine Levels

Homocysteine is an amino acid linked to endothelial damage and atherogenesis. Elevated homocysteine levels (>15 µmol/L) are associated with increased ASCVD risk, although lowering homocysteine levels has not consistently shown a reduction in cardiovascular events. (63, 67)

Examples of Homocysteine Tests

Coronary Artery Calcium Score

Coronary artery calcium (CAC) score quantifies the burden of coronary atherosclerosis and is a strong predictor of future cardiovascular events. A CAC score of 0 indicates a low risk of cardiovascular events, while higher scores indicate higher risk and the need for more aggressive preventive measures. CAC scoring is particularly useful in intermediate-risk patients to refine risk assessment and guide treatment decisions. (75)

Blood Pressure Monitoring

Hypertension is another significant risk factor for ASCVD, and the cooccurrence of high blood pressure with high cholesterol synergistically increases the risk of cardiovascular events. Adequate blood pressure (BP) management mitigates this risk and improves cardiovascular outcomes. 

Non-Hypertensive Patients

The U.S. Preventive Services Task Force (USPSTF) recommends annual screening for hypertension for adults aged 40 years or older and for those who are at increased risk for high blood pressure. 

Hypertensive Patients

Once hypertension is diagnosed, BP should be monitored more frequently. The guidelines recommend follow-up visits every 1-6 months (depending on the therapeutic interventions used to treat) until blood pressure is controlled. After achieving the target BP, follow-up visits can be spaced out. (89) 

[signup]

Key Takeaways

  • Managing elevated cholesterol is crucial for individuals over 40 to reduce the risk of cardiovascular diseases and prevent adverse cardiovascular events.
  • Regular lab testing, including lipid panels, hs-CRP, thyroid function tests, liver function tests, blood sugar, and blood pressure monitoring, provides the required information to stratify cardiovascular risk.
  • By understanding and interpreting these test results, healthcare providers can develop personalized heart-healthy treatment plans that incorporate dietary modifications, physical activity, medications, and lifestyle changes to optimize lipid profiles and reduce overall risk for cardiovascular disease.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!

References

  1. Abdullah, S. M., Defina, L. F., Leonard, D., et al. (2018). Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. Circulation, 138(21), 2315–2325. https://doi.org/10.1161/circulationaha.118.034273
  2. Achuff, J. (2024, February 5). How to test and interpret total cholesterol levels: A functional medicine perspective. Rupa Health. https://www.rupahealth.com/post/how-to-test-and-interpret-total-cholesterol-levels-a-functional-medicine-perspective
  3. Achuff, J. (2024, February 6). How to lower your patient's triglycerides using root cause medicine. Rupa Health. https://www.rupahealth.com/post/how-to-lower-your-patients-triglycerides-using-root-cause-medicine
  4. American Diabetes Association Professional Practice Committee. (2023). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care, 47(Supplement 1), S20–S42. https://doi.org/10.2337/dc24-s002
  5. American Diabetes Association Professional Practice Committee. (2023). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care, 47(Supplement 1), S179–S218. https://doi.org/10.2337/dc24-s010
  6. Anderson, S. (2022, May 19). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health. https://www.rupahealth.com/post/5-things-to-do-after-a-heart-attack
  7. Anderson, S. (2022, July 8). Over 40% of Americans are Deficient in This Vitamin: Here are The Symptoms To Look Out For. Rupa Health. https://www.rupahealth.com/post/what-causes-vitamin-d-deficiency
  8. Apo B Test. Cleveland Clinic. https://my.clevelandclinic.org/health/diagnostics/24992-apolipoprotein-b-test
  9. APOB. Rupa Health. https://www.rupahealth.com/biomarkers/apob
  10. Arnett, D. K., Blumenthal, R. S., Albert, M. A., et al. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation, 140(11), e596–e646. https://doi.org/10.1161/cir.0000000000000678
  11. Bertolotti, M., Mussi, C., Pellegrini, E., et al. (2014). Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. Clinical Interventions in Aging, 9, 425–432. https://doi.org/10.2147/cia.s57714
  12. Butalia, S., Chu, L. M., Dover, D. C., et al. (2024). Association Between Hemoglobin A1c and Development of Cardiovascular Disease in Canadian Men and Women Without Diabetes at Baseline: A Population‐Based Study of 608 474 Adults. Journal of the American Heart Association. Cardiovascular and Cerebrovascular Disease, 13(9). https://doi.org/10.1161/jaha.123.031095
  13. Choi, H. Y. J. (2024). Coronary Artery Calcium Scoring for Prevention of Cardiovascular Disease. American Family Physician, 106(1), 93–94. https://www.aafp.org/pubs/afp/issues/2022/0700/diagnostic-tests-coronary-artery-calcium-scoring.html
  14. Christie, J. (2022, December 6). The ultimate guide to thyroid hormones. Rupa Health. https://www.rupahealth.com/post/a-complete-guide-to-thyroid-hormones-a-functional-medicine-approach
  15. Cleeman, J. I. (1998). Detection and evaluation of dyslipoproteinemia. Endocrinology and Metabolism Clinics of North America, 27(3), 597–611. https://doi.org/10.1016/s0889-8529(05)70028-1
  16. Cloyd, J. (2022, October 4). 4 nutrition hacks that lower high cholesterol. Rupa Health. https://www.rupahealth.com/post/4-nutrition-hacks-to-lower-high-cholesterol
  17. Cloyd, J. (2022, November 17). Subclinical hypothyroidism: Signs, symptoms, & treatments. Rupa Health. https://www.rupahealth.com/post/subclinical-hypothyroidism-signs-symptoms-treatments
  18. Cloyd, J. (2023, March 8). Bile Acids 101: Testing, Interpreting, Treatment. Rupa Health. https://www.rupahealth.com/post/stool-bile-acids-101
  19. Cloyd, J. (2023, April 10). A Functional Medicine Hypertension Protocol. Rupa Health. https://www.rupahealth.com/post/functional-medicine-hypertension-protocol
  20. Cloyd, J. (2023, May 1). A Functional Medicine Protocol for Coronary Artery Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-coronary-artery-disease
  21. Cloyd, J. (2023, May 24). A Functional Medicine Hypothyroidism Protocol: Comprehensive Testing, Supplements, and Integrative Nutrition. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-hypothyroidism-protocol-comprehensive-testing-supplements-and-integrative-nutrition
  22. Cloyd, J. (2023, June 19). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-post-stroke-protocol-testing-supplements-and-integrative-therapy-options
  23. Cloyd, J. (2023, October 23). What Do Homocysteine Test Results Tell Us? Rupa Health. https://www.rupahealth.com/post/what-do-homocysteine-test-results-tell-us
  24. Cloyd, J. (2023, December 5). Inflammation and Heart Disease: A Functional Medicine Approach to Prevention and Treatment. Rupa Health. https://www.rupahealth.com/post/inflammation-and-heart-disease-a-functional-medicine-approach-to-prevention-and-treatment
  25. Cloyd, J. (2023, December 11). How to Interpret Your CRP Blood Test. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-crp-blood-test
  26. Cloyd, J. (2023, December 26). How to Interpret An HbA1c Test and What it Means For Your Patient's Health. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-an-hba1c-test-and-what-it-means-for-your-patients-health
  27. Cloyd, J. (2024, January 2). A functional medicine approach to prediabetes. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-prediabetes
  28. Cloyd, J. (2024, January 22). Interpreting Liver Enzyme Tests: ALT, AST, and ALP in Liver Health Monitoring. Rupa Health. https://www.rupahealth.com/post/interpreting-liver-enzyme-tests-alt-ast-and-alp-in-liver-health-monitoring
  29. Cloyd, J. (2024, March 4). The Role of Statins in Managing High Cholesterol: Benefits and Side Effects. Rupa Health. https://www.rupahealth.com/post/the-role-of-statins-in-managing-high-cholesterol-benefits-and-side-effects
  30. Cloyd, J. (2024, March 5). How to lower LDL cholesterol naturally: Evidence-Based recommendations. Rupa Health. https://www.rupahealth.com/post/how-to-lower-ldl-cholesterol-naturally-evidence-based-recommendations
  31. Cloyd, J. (2024, March 6). How to Increase HDL Cholesterol: A Root Cause Medicine Approach. Rupa Health. https://www.rupahealth.com/post/how-to-increase-hdl-cholesterol-a-root-cause-medicine-approach
  32. Cloyd, J. (2024, August 30). High ALT Levels Explained: Causes, Symptoms, and Key Biomarkers. Rupa Health. https://www.rupahealth.com/post/high-alt-levels-explained-causes-symptoms-and-key-biomarkers
  33. Cloyd, J. (2024, August 30). Understanding High AST Levels: Causes and Implications. Rupa Health. https://www.rupahealth.com/post/understanding-high-ast-levels-causes-and-implications
  34. Cloyd, J. (2024, September 12). High-Intensity Statins: A Guide for Optimal Heart Health. Rupa Health. https://www.rupahealth.com/post/high-intensity-statins-a-guide-for-optimal-heart-health
  35. Cloyd, J. (2024, September 13). Your Guide to Hyperglycemia (High Blood Sugar): Causes, Symptoms, Diagnosis, and Treatment Options. Rupa Health. https://www.rupahealth.com/post/your-guide-to-hyperglycemia-high-blood-sugar-causes-symptoms-diagnosis-and-treatment-options
  36. Cloyd, K. (2023, December 19). How to interpret your lipid panel results. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-lipid-panel-results
  37. Coronary Artery Calcification. (2022, May 9). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22953-coronary-artery-calcification
  38. Craig, M., Yarrarapu, S. N. S., & Malik, A. (2023, August 8). Biochemistry, Cholesterol. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK513326/
  39. Daglis, S. (2024, February 1). Heart Health in Menopause: Understanding and Managing Cardiovascular Risks. Rupa Health. https://www.rupahealth.com/post/heart-health-in-menopause-understanding-and-managing-cardiovascular-risks
  40. Daglis, S. (2024, March 7). Emerging Biomarkers for Lipid Disorders: Beyond Traditional Lipid Profiles. Rupa Health. https://www.rupahealth.com/post/emerging-biomarkers-for-lipid-disorders-beyond-traditional-lipid-profiles
  41. Daglis, S. (2024, August 15). Comprehensive Guide to High Alkaline Phosphatase: Symptoms, Diagnosis, and Effective Treatments. Rupa Health. https://www.rupahealth.com/post/comprehensive-guide-to-high-alkaline-phosphatase-symptoms-diagnosis-and-effective-treatments
  42. Galimberti, F., Casula, M., & Olmastroni, E. (2023). Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment. Pharmacological Research, 195, 106873–106873. https://doi.org/10.1016/j.phrs.2023.106873
  43. Feingold, K. R. (2019). Dyslipidemia in Patients with Diabetes. In K. Feingold , B. Anawalt, M. R. Blackman, & et al. (Eds.), Endotext [Internet]. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305900/
  44. Floriani, C., Gencer, B., Collet, T.-H., et al. (2017). Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. European Heart Journal, 39(7), 503–507. https://doi.org/10.1093/eurheartj/ehx050
  45. Free Thyroxine. Rupa Health. https://www.rupahealth.com/biomarkers/ft4
  46. Free Triiodothyronine. Rupa Health. https://www.rupahealth.com/biomarkers/ft3
  47. Gamma-Glutamyl Transferase. Rupa Health. https://www.rupahealth.com/biomarkers/ggt
  48. Genest, J. (2010). C-reactive protein: Risk factor, biomarker and/or therapeutic target? Canadian Journal of Cardiology, 26, 41A44A. https://doi.org/10.1016/s0828-282x(10)71061-8
  49. Glucose. Rupa Health. https://www.rupahealth.com/biomarkers/glucose
  50. Goldsborough, E., Tasdighi, E., & Blaha, M. J. (2023). Assessment of cardiovascular disease risk: a 2023 update. Current Opinion in Lipidology, 34(4), 162–173. https://doi.org/10.1097/mol.0000000000000887
  51. Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2018). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24). https://doi.org/10.1016/j.jacc.2018.11.003
  52. Gu, Y., Meng, G., Zhang, Q., et al. (2020). Thyroid function and lipid profile in euthyroid adults: the TCLSIH cohort study. Endocrine, 70(1), 107–114. https://doi.org/10.1007/s12020-020-02312-6
  53. High Cholesterol. (2023). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/symptoms-causes/syc-20350800
  54. hs-CRP. Rupa Health. https://www.rupahealth.com/biomarkers/hs-crp
  55. Huang, F., Wu, L., Qiu, Y., et al. (2019). The role of free triiodothyronine in high-density lipoprotein cholesterol metabolism. Medicine, 98(36), e17016. https://doi.org/10.1097/md.0000000000017016
  56. Hussain, A., Ali, I., Ijaz, M., et al. (2017). Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Therapeutic Advances in Endocrinology and Metabolism, 8(4), 51–57. https://doi.org/10.1177/2042018817692296
  57. Ibrahim, M. A., Asuka, E., & Jialal, I. (2020, October 24). Hypercholesterolemia. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459188/
  58. Khakham, C. (2023, April 6). Understanding Your Risk of Cardiovascular Disease With Functional Medicine Labs. Rupa Health. https://www.rupahealth.com/post/understanding-your-risk-of-cardiovascular-disease-with-functional-medicine-labs
  59. Khavandi, M., Duarte, F., Ginsberg, H. N., et al. (2017). Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Current Cardiology Reports, 19(1). https://doi.org/10.1007/s11886-017-0818-1
  60. Kresge, K. (2022, May 20). 3 natural ways to lower cholesterol levels. Rupa Health. https://www.rupahealth.com/post/natural-treatments-for-high-cholesterol
  61. Lipoprotein (a). Rupa Health. https://www.rupahealth.com/biomarkers/lp-a
  62. Mannucci, E., Dicembrini, I., Lauria, A., et al. (2013). Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes? Diabetes Care, 36(Supplement_2), S259–S263. https://doi.org/10.2337/dcs13-2018
  63. Marcus, J., Sarnak, M. J., Menon, V., et al. (2007). Homocysteine lowering and cardiovascular disease risk: Lost in translation. Canadian Journal of Cardiology, 23(9), 707–710. https://doi.org/10.1016/s0828-282x(07)70814-0
  64. Mehta, A., Vasquez, N., Ayers, C. R., et al. (2022). Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. Journal of the American College of Cardiology, 79(8), 757–768. https://doi.org/10.1016/j.jacc.2021.11.058
  65. Nunes, V. S., da Silva Ferreira, G., & Quintão, E. C. R. (2022). Cholesterol metabolism in aging simultaneously altered in liver and nervous system. Aging, 14(3). https://doi.org/10.18632/aging.203880
  66. Peng, K., Li, X., Wang, Z., et al. (2022). Association of low-density lipoprotein cholesterol levels with the risk of mortality and cardiovascular events: A meta-analysis of cohort studies with 1,232,694 participants. Medicine, 101(48), e32003. https://doi.org/10.1097/MD.0000000000032003
  67. Refsum, H., Ueland, P. M., Nygård, O., et al. (1998). Homocysteine and Cardiovascular Disease. Annual Review of Medicine, 49(1), 31–62. https://doi.org/10.1146/annurev.med.49.1.31
  68. Rey, J. B., & Hawks, M. (2022). Prevention or Delay of Type 2 Diabetes Mellitus: Recommendations From the American Diabetes Association. American Family Physician, 105(4), 438–439. https://www.aafp.org/pubs/afp/issues/2022/0400/p438.html
  69. Ridker, P. M. (2001). High-Sensitivity C-Reactive Protein. Circulation, 103(13), 1813–1818. https://doi.org/10.1161/01.cir.103.13.1813
  70. Ridker, P. M. (2003). High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. The American Journal of Cardiology, 92(4), 17–22. https://doi.org/10.1016/s0002-9149(03)00774-4
  71. Ridker, P. M. (2016). A Test in Context: High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology, 67(6), 712–723. https://doi.org/10.1016/j.jacc.2015.11.037
  72. Rugge, B., Balshem, H., Sehgal, R., et al. (2011). Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism [Internet]. In www.ncbi.nlm.nih.gov. Agency for Healthcare Research and Quality (US). https://www.ncbi.nlm.nih.gov/books/NBK83508/
  73. Sánchez-Quesada, J. L., Vinagre, I., de Juan-Franco, E., et al. (2012). Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. The American Journal of Cardiology, 110(1), 67–71. https://doi.org/10.1016/j.amjcard.2012.02.051
  74. Satoh, M., Ohkubo, T., Asayama, K., et al. (2015). Combined Effect of Blood Pressure and Total Cholesterol Levels on Long-Term Risks of Subtypes of Cardiovascular Death. Hypertension, 65(3), 517–524. https://doi.org/10.1161/hypertensionaha.114.04639
  75. Schade, D. S., Hickey, M., & Eaton, R. P. (2023). Interpreting the Coronary Artery Calcium Score – Critical Information for the Practicing Physician. The American Journal of Medicine, 136(11), 1070–1075. https://doi.org/10.1016/j.amjmed.2023.08.005
  76. Screening for High Blood Pressure in Adults: Recommendation Statement. (2016). American Family Physician, 93(4), 300–302. https://www.aafp.org/pubs/afp/issues/2016/0215/p300.html
  77. Soffer, D. E., Marston, N. A., Maki, K. C., et al. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2024.08.013
  78. Sweetnich, J. (2023, April 25). Complementary and Integrative Medicine Approaches to Type 2 Diabetes Management. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-medicine-approaches-to-type-2-diabetes-management
  79. Sweetnich, J. (2023, May 19). Overview of The Liver 101: Top Conditions, Specialty Testing, and Integrative Medicine Treatment Options. Rupa Health. https://www.rupahealth.com/post/overview-liver-101-top-conditions-and-testing
  80. The Blood Pressure Lowering Treatment Trialists' Collaboration. (2021). Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet, 397(10285), 1625–1636. https://doi.org/10.1016/S0140-6736(21)00590-0
  81. Thyroid Disease. (2020, April 19). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/8541-thyroid-disease
  82. Thyroid-Stimulating Hormone. Rupa Health. https://www.rupahealth.com/biomarkers/tsh
  83. VLDL. (2022, December 5). Cleveland Clinic. https://my.clevelandclinic.org/health/articles/24540-vldl-cholesterol
  84. Wang, F., Tan, Y., Wang, C., et al. (2012). Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. The Journal of Clinical Endocrinology and Metabolism, 97(8), 2724–2731. https://doi.org/10.1210/jc.2012-1133
  85. Wang, Y., Guo, P., Liu, L., et al. (2021). Mendelian Randomization Highlights the Causal Role of Normal Thyroid Function on Blood Lipid Profiles. Endocrinology, 162(5). https://doi.org/10.1210/endocr/bqab037
  86. Weinberg, J. L. (2022, September 7). An Integrative Medicine Approach to Hypothyroidism. Rupa Health. https://www.rupahealth.com/post/understanding-hypothyroidism-and-how-to-treat-it-naturally
  87. Weinberg, J. L. (2023, June 1). A Functional Medicine Non Alcoholic Fatty Liver Disease (NAFLD) Protocol: Testing, Nutrition, and Supplements. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-non-alcoholic-fatty-liver-disease-nafld-protocol-testing-nutrition-and-supplements
  88. What Is Heart-Healthy Living? (2022, March 24). National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/heart-healthy-living
  89. Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6). https://doi.org/10.1161/hyp.0000000000000065
  90. Yao, C., Yen, T.-Y., Sandy Huey-Jen Hsu, et al. (2023). Glycative Stress, Glycated Hemoglobin, and Atherogenic Dyslipidemia in Patients with Hyperlipidemia. Cells, 12(4), 640–640. https://doi.org/10.3390/cells12040640
Jaime Cloyd
Author
Dr. Jaime Cloyd ND
Naturopathic Physician based in the greater Seattle area
Medically Reviewed by
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.
Sign up free
Browse the lab catalog

Latest Articles

View more on Metabolic Management
Coronary Calcium Scoring: What is This Important Test, What Does it Tell Us About Our Heart, and What Does it Hide?Coronary Calcium Scoring: What is This Important Test, What Does it Tell Us About Our Heart, and What Does it Hide?
Coronary Calcium Scoring: What is This Important Test, What Does it Tell Us About Our Heart, and What Does it Hide?
,
December 18, 2024
Jessica Christie
Jessica Christie, ND, CNS
December 18, 2024
Red Blood Cells and Inflammation: Leveraging CBC and Metabolic Biomarkers for Early Disease InsightsRed Blood Cells and Inflammation: Leveraging CBC and Metabolic Biomarkers for Early Disease Insights
Red Blood Cells and Inflammation: Leveraging CBC and Metabolic Biomarkers for Early Disease Insights
Dr. Chris Magryta, MD
December 13, 2024
Dr. ,
December 13, 2024
The Predictive Power of Micronutrient Cofactor Testing in Disease Prevention and ManagementThe Predictive Power of Micronutrient Cofactor Testing in Disease Prevention and Management
The Predictive Power of Micronutrient Cofactor Testing in Disease Prevention and Management
Dr. Chris Magryta, MD
December 13, 2024
Dr. ,
December 13, 2024
Is TSH the Only Lab Value That Evaluates Thyroid Dysfunction and Disease?Is TSH the Only Lab Value That Evaluates Thyroid Dysfunction and Disease?
Is TSH the Only Lab Value That Evaluates Thyroid Dysfunction and Disease?
Dr. Chris Magryta, MD
December 13, 2024
Dr. ,
December 13, 2024
See all Articles
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

Register Here

Hey practitioners! 👋 Join Dr. Terry Wahls for a 3-week bootcamp on integrating functional medicine into conventional practice, focusing on complex cases like Multiple Sclerosis. Learn to analyze labs through a functional lens, perform nutrition-focused physical exams, and develop personalized care strategies. Register Here.

Register Here